INMUNE BIO INC. (INMB)

Every figure this model derived for INMB, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 1,042,000 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 18,411,000 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents 2026-06-30
current assets 23,799,000 AssetsCurrent 2026-06-30
current liabilities 5,890,000 LiabilitiesCurrent 2026-06-30
equity 20,362,000 StockholdersEquity 2026-06-30
interest expense 0 InterestExpenseDebt 2025-12-31
ocf -14,961,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 50,000 Revenues 2025-12-31
sbc 9,155,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up INMB on one particular measure came for.

RatioValue
current ratio4.04
current ratio reported4.04
dilution pct24.15
growth cv1.73
revenue growth257.14
revenue growth per share187.67
roic-817.74
rule of 40-40132.86

What to be careful about

What this model itself distrusts about INMB's figures. Written by the derivation as it ran, not added afterwards.